Journal profile · Nursing-Pharmacology (nursing)
Bezopasnost' i risk farmakoterapii
ISSN 2312-7821 · eISSN 2619-1164 · Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation · Russian Federation
Bezopasnost' i risk farmakoterapii: diamond open access (no APC); no APC; review about 12 weeks (community reports); 42 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Bezopasnost' i risk farmakoterapii is published by Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation. By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Medical and Pharmaceutic Studies and Pharmacogenetics and Drug Metabolism, together about 43.6% of its articles. Its main subfields are Pharmacology. (generated from OpenAlex topic counts and CAS ranking data)
«Безопасность и риск фармакотерапии» – научно-практический рецензируемый журнал открытого доступа, учредителем которого выступает федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации (ФГБУ «НЦЭСМП» Минздрава России). Цель журнала – освещение научных достижений и практического опыта в области обеспечения безопасности лекарственных средств и снижения рисков фармакотерапии.
From the journal's Aims & Scope
Research area (LetPub): Nursing-Pharmacology (nursing)
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics25.9%
- Medical and Pharmaceutic StudiesPharmacology, Toxicology and Pharmaceutics12.6%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics5.1%
- Healthcare RegulationHealth Professions5.1%
- Pharmaceutical industry and healthcarePharmacology, Toxicology and Pharmaceutics5%
- Pharmaceutical Practices and Patient OutcomesMedicine4.7%
- Pharmaceutical studies and practicesMedicine3.8%
- Pharmacy and Medical PracticesPharmacology, Toxicology and Pharmaceutics3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology (nursing) | Q2 | 5/10 | — |
| Health Professions (miscellaneous) | Q3 | 63/101 | — |
| Pharmacy | Q3 | 35/52 | — |
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | Q3 | 39/57 | — |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
RSCI, ВАК, Белый списокPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 0.7LetPub ·
- SJR 2026-06
- 0.14LetPub ·
- SNIP 2026-06
- 0.25LetPub ·
- h-index
- 10OpenAlex ·
- i10-index
- 13OpenAlex ·
- 2-year mean citedness
- 0.95OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 388 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 34 | 34 | 135 |
| 2025 | 42 | 42 | 126 |
| 2024 | 37 | 37 | 106 |
| 2023 | 47 | 47 | 86 |
| 2022 | 39 | 39 | 104 |
| 2021 | 29 | 29 | 112 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Cover letter
- Required
Policy excerpts from the journal's websiteAuthorship, Publication ethics
- Authorship
Follows ICMJE recommendations Model summary
авторы при подготовке статьи придерживались Рекомендаций ICMJE по проведению, описанию, редактированию и публикации результатов научной работы в медицинских журналах
Source ↗Publisher website ·- Publication ethics
Follows COPE guidelines Model summary
В случае обнаружения недобросовестного поведения со стороны автора, в том числе выявления плагиата, фабрикации или фальсификации данных редакция руководствуется правилами COPE
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
- Country or region
- Russian Federation
- Language
- Russian
- ISSN
- 2312-7821
- Electronic ISSN
- 2619-1164
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Bezopasnost' i risk farmakoterapii
How long does peer review take at Bezopasnost' i risk farmakoterapii?
Authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Bezopasnost' i risk farmakoterapii?
According to the journal's author guidelines: Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Bezopasnost' i risk farmakoterapii?
According to LetPub and DOAJ records, Bezopasnost' i risk farmakoterapii is indexed in Scopus and DOAJ.
Is Bezopasnost' i risk farmakoterapii open access, and what is the APC?
Bezopasnost' i risk farmakoterapii is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .